Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539864 · ClinicalTrials.gov registry record · Phase 3
Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV
A Phase 3 study of Influenza, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 602
- Enrollment target
- 5
- Study locations
NCT00539864 is a Phase 3 study of Influenza that has completed, run by Protein Sciences Corporation. The registered enrollment target is 602 participants, below the 36,800-participant average among 156 other Influenza trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 2 states.
The verdict
NCT00539864, a Phase 3 study of Influenza, has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 602 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study was to evaluate and compare the safety, reactogenicity, immunogenicity, relative efficacy and effectiveness of FluBlok to a licensed trivalent influenza vaccine (TIV)in healthy adults age 50-64 years.
Conditions Studied
Interventions
- BIOLOGICAL FluBlok Influenza Vaccination
- BIOLOGICAL TIV (Fluzone) Influenza Vaccination
Study Locations (5)
California
- Kaiser Permanente Pediatric Clinic - Fresno - Fresno
- Kaiser Permanente Pediatric Clinic - Hayward - Hayward
- Kaiser Permanente Pediatric Clinic - Roseville - Roseville
- Kaiser Permanente Pediatric Clinic - Sacramento - Sacramento
Hawaii
- Kaiser Permanente - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539864
The ClinicalTrials.gov registry entry for NCT00539864 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 602 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,800-participant average among 156 other Influenza trials with a reported enrollment target (98% lower). The listed sponsor is Protein Sciences Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which FluBlok Influenza Vaccination is the first listed.
NCT00539864 reports 5 study locations spanning 2 distinct geographic areas - top geographies include California, Hawaii.
Frequently Asked Questions
What is clinical trial NCT00539864 about?
NCT00539864 is a clinical study titled "Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV". The purpose of this study was to evaluate and compare the safety, reactogenicity, immunogenicity, relative efficacy and effectiveness of FluBlok to a licensed trivalent influenza vaccine (TIV)in healthy adults age 50-64 years.
What is the current status of trial NCT00539864?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 602 participants. The study started on 2007-09. Estimated completion is 2008-04.
What conditions does trial NCT00539864 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT00539864?
The interventions under investigation include: FluBlok Influenza Vaccination (BIOLOGICAL), TIV (Fluzone) Influenza Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT00539864?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00539864 being conducted?
This trial has 5 study locations across California, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
ACTIVE NOT RECRUITING · Phase 3
-
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
COMPLETED · Phase 3
-
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
COMPLETED · Phase 3
-
Study of Quadrivalent Influenza Vaccine Among Children
COMPLETED · Phase 3
-
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.